Vichai Senthong1,2, Jennifer L Kirsop3, W H Wilson Tang4,5,6. 1. Department of Cardiovascular Medicine, Heart and Vascular Institute, 9500 Euclid Avenue, Desk J3-4, Cleveland, OH, 44915, USA. 2. Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. 3. Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland, OH, USA. 4. Department of Cardiovascular Medicine, Heart and Vascular Institute, 9500 Euclid Avenue, Desk J3-4, Cleveland, OH, 44915, USA. tangw@ccf.org. 5. Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland, OH, USA. tangw@ccf.org. 6. Center for Clinical Genomics, Cleveland Clinic, Cleveland, OH, USA. tangw@ccf.org.
Abstract
INTRODUCTION: Heart failure (HF) is a complex clinical syndrome with diverse risk factors and etiologies, differing underlying pathophysiology, and large phenotypic heterogeneity. RECENT FINDINGS: Advances in imaging techniques coupled with clinical trials that targeted only in those with impaired left ventricular ejection fraction (LVEF) have largely shaped the current management strategy for HF that focuses predominantly in patients with systolic HF. In contrast, there are no effective treatments for HF with preserved ejection fraction (HFpEF). Instead of this "one-size-fits-all" approach to treatment, better precision to define HF phenotypic classifications may lead to more efficient and effective HF disease management. CONCLUSION: Integrating variables-including clinical variables, HF biomarkers, imaging, genotypes, metabolomics, and proteomics-can identify different pathophysiologies, lead to more precise phenotypic classification, and warrant investigation in future clinical trials.
INTRODUCTION:Heart failure (HF) is a complex clinical syndrome with diverse risk factors and etiologies, differing underlying pathophysiology, and large phenotypic heterogeneity. RECENT FINDINGS: Advances in imaging techniques coupled with clinical trials that targeted only in those with impaired left ventricular ejection fraction (LVEF) have largely shaped the current management strategy for HF that focuses predominantly in patients with systolic HF. In contrast, there are no effective treatments for HF with preserved ejection fraction (HFpEF). Instead of this "one-size-fits-all" approach to treatment, better precision to define HF phenotypic classifications may lead to more efficient and effective HF disease management. CONCLUSION: Integrating variables-including clinical variables, HF biomarkers, imaging, genotypes, metabolomics, and proteomics-can identify different pathophysiologies, lead to more precise phenotypic classification, and warrant investigation in future clinical trials.
Authors: Bonnie Ky; Benjamin French; Wayne C Levy; Nancy K Sweitzer; James C Fang; Alan H B Wu; Lee R Goldberg; Mariell Jessup; Thomas P Cappola Journal: Circ Heart Fail Date: 2012-02-23 Impact factor: 8.790
Authors: Ravi V Shah; Annabel A Chen-Tournoux; Michael H Picard; Roland R J van Kimmenade; James L Januzzi Journal: Eur J Heart Fail Date: 2010-06-05 Impact factor: 15.534
Authors: Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort Journal: N Engl J Med Date: 2013-09-05 Impact factor: 91.245
Authors: W H Wilson Tang; Matthias Dupont; Adrian F Hernandez; Adriaan A Voors; Amy P Hsu; G Michael Felker; Javed Butler; Marco Metra; Stefan D Anker; Richard W Troughton; Stephen S Gottlieb; John J McMurray; Paul W Armstrong; Barry M Massie; Robert M Califf; Christopher M O'Connor; Randall C Starling Journal: JACC Heart Fail Date: 2014-11-11 Impact factor: 12.035
Authors: Kevin Damman; Dirk J Van Veldhuisen; Gerjan Navis; Vishal S Vaidya; Tom D J Smilde; B Daan Westenbrink; Joseph V Bonventre; Adriaan A Voors; Hans L Hillege Journal: Heart Date: 2010-08 Impact factor: 5.994
Authors: Benjamin Meder; Frank Rühle; Tanja Weis; Georg Homuth; Andreas Keller; Jennifer Franke; Barbara Peil; Justo Lorenzo Bermejo; Karen Frese; Andreas Huge; Anika Witten; Britta Vogel; Jan Haas; Uwe Völker; Florian Ernst; Alexander Teumer; Philipp Ehlermann; Christian Zugck; Frauke Friedrichs; Heyo Kroemer; Marcus Dörr; Wolfgang Hoffmann; Bernhard Maisch; Sabine Pankuweit; Volker Ruppert; Thomas Scheffold; Uwe Kühl; Hans-Peter Schultheiss; Reinhold Kreutz; Georg Ertl; Christiane Angermann; Philippe Charron; Eric Villard; Françoise Gary; Richard Isnard; Michel Komajda; Matthias Lutz; Thomas Meitinger; Moritz F Sinner; H-Erich Wichmann; Michael Krawczak; Boris Ivandic; Dieter Weichenhan; Goetz Gelbrich; Nour-Eddine El-Mokhtari; Stefan Schreiber; Stephan B Felix; Gerd Hasenfuß; Arne Pfeufer; Norbert Hübner; Stefan Kääb; Eloisa Arbustini; Wolfgang Rottbauer; Norbert Frey; Monika Stoll; Hugo A Katus Journal: Eur Heart J Date: 2013-07-12 Impact factor: 29.983
Authors: Rusty L Montgomery; Thomas G Hullinger; Hillary M Semus; Brent A Dickinson; Anita G Seto; Joshua M Lynch; Christianna Stack; Paul A Latimer; Eric N Olson; Eva van Rooij Journal: Circulation Date: 2011-09-06 Impact factor: 29.690
Authors: Justin L Grodin; Antonio L Perez; Yuping Wu; Adrian F Hernandez; Javed Butler; Marco Metra; G Michael Felker; Adriaan A Voors; John J McMurray; Paul W Armstrong; Robert M Califf; Randall C Starling; Christopher M O'Connor; W H Wilson Tang Journal: JACC Heart Fail Date: 2015-10 Impact factor: 12.035
Authors: Rudolf A de Boer; Dirk J A Lok; Tiny Jaarsma; Peter van der Meer; Adriaan A Voors; Hans L Hillege; Dirk J van Veldhuisen Journal: Ann Med Date: 2010-12-28 Impact factor: 4.709
Authors: Mengmeng Liu; Liza S Köster; Geoffrey T Fosgate; Christopher C Chadwick; Íñigo Sanz-González; Peter David Eckersall; Paul R Wotton; Anne T French Journal: J Vet Intern Med Date: 2020-05-12 Impact factor: 3.333